CIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes
Randomized placebo-controlled studyAssessing 3 months of CIR-0602K for increasing glucose time-in-range, reducing HbA1c and total daily insulin dose, and improving cardiovascular biomarkers and vascular functionSupported by Breakthrough T1D and ongoing at University of Virginia School of MedicineTopline data…
News provided by PR Newswire.
